SHANGHAI – High-flying CAR T developer, Kite Pharma Inc., of Santa Monica, Calif., is making a push into China and Japan. A pair of deals – Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Daiichi-Sankyo Co. Inc. – features lead asset, KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for which the company is on track to submit a BLA to the FDA later this year.
SHANGHAI – Taiwan Liposome Co. (TLC) is hoping to give patients with osteoarthritis of the knee a better option for pain management with TLC599, a steroid API wrapped in a sustained release liposome delivery package.
SHANGHAI – Taiwan Liposome Co. (TLC) is hoping to give patients with osteoarthritis of the knee a better option for pain management with TLC599, a steroid API wrapped in a sustained release liposome delivery package. The company released positive top line results from a phase I/II data for a trial in Taiwan and Australia, and kicked off a phase II trial in both places with plans underway for China and the U.S.
SHANGHAI – Small-molecule oncology drug developer, Ascentage Pharma Group, of Taizhou, Zhejiang, has raised ¥500 million (US$72 million) from Future Industry Investment Fund, a private equity fund managed by China’s State Development & Investment Corporation Fund Management Corp. Ltd. (SDIC).
SHANGHAI – The latest Chinese biopharma to receive a generous round of financing, Ascletis Pharmaceuticals Co. Ltd., of Hangzhou and Shaoxing, received $100 million from China-based venture capital firms.
SHANGHAI – Small-molecule oncology drug developer, Ascentage Pharma Group, of Taizhou, Zhejiang, has raised ¥500 million (US$72 million) from Future Industry Investment Fund, a private equity fund managed by China's State Development & Investment Corporation Fund Management Corp. Ltd. (SDIC).
SHANGHAI – The latest Chinese biopharma to receive a generous round of financing, Ascletis Pharmaceuticals Co. Ltd., of Hangzhou and Shaoxing, received $100 million from China-based venture capital firms.
SHANGHAI – Newly founded biopharma Harbour Biomed Therapeutics Ltd., of Shanghai, has acquired privately held Harbour Antibody BV, of Cambridge, Mass. The cash-and-equity deal was inked after Harbour Biomed secured $50 million in venture financing from life science investors Adventech and Legend.
SHANGHAI – Newly founded biopharma Harbour Biomed Therapeutics Ltd., of Shanghai, has acquired privately held Harbour Antibody BV, of Cambridge, Mass. The cash-and-equity deal was inked after Harbour Biomed secured $50 million in venture financing from life science investors Adventech and Legend.
